In yesterday’s Wall Street session, Moderna Inc (NASDAQ:MRNA) shares traded at $39.51, up 7.22% from the previous session.
MRNA stock price is now -31.67% away from the 50-day moving average and -59.39% away from the 200-day moving average. The market capitalization of the company currently stands at $14.09B.
With the price target maintained at $58, HSBC Securities recently Upgraded its rating from Hold to Buy for Moderna Inc (NASDAQ: MRNA). On November 15, 2024, Wolfe Research recently initiated its ‘Underperform’ rating on the stock quoting a target price of $40, while ‘Bernstein’ rates the stock as ‘Mkt Perform’
In other news, Hoge Stephen, President sold 277 shares of the company’s stock on Nov 11 ’24. The stock was sold for $12,771 at an average price of $46.10. Upon completion of the transaction, the President now directly owns 1,443,248 shares in the company, valued at $57.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11 ’24, Officer Hoge Stephen bought 277 shares of the business’s stock. A total of $12,771 was incurred on buying the stock at an average price of $46.10. A total of 10.83% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $35.80 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.39, and a quick ratio of 4.20. The fifty day moving average price for MRNA is $58.5626 and a two-hundred day moving average price translates $97.57143 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-09-30. The net profit margin was -43.84% and return on equity was -17.52% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $1.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.69 percent.
